Targeted Protein Degradation Technologies (Paperback)

Targeted Protein Degradation Technologies offers a comprehensive exploration of the field of targeted protein degradation, from its latest scientific advancements to its potential therapeutic applications. This book begins with a foundational introduction to the mechanisms of protein degradation, followed by an in-depth look at both protease-mediated and lysosome-mediated degradation pathways. The text delves into a range of cutting-edge technologies, including PROTAC, AbTAC, molecular glues, hydrophobic tagging, LYTAC, GlueTAC, and AUTAC. It then explores the development of degraders for specific proteins, such as signal transduction receptors, membrane proteins, and transcription factors. This book concludes with a focused discussion on the clinical applications of targeted protein degradation and provides an insight into the future directions for this field.

This book serves as an invaluable resource for researchers and professionals in molecular biology, cell biology, and related disciplines, particularly those involved in protein degradation and the development of novel therapeutic strategies.

• Offers a foundational introduction to the mechanisms of protein degradation
• Features a range of targeted protein degradation technologies and covers the latest advances in each area
• Explores the clinical potential of protein degraders in drug discovery

Dr. Jiangjiang Qin is currently a Professor of Cancer Pharmacology and Drug Discovery at the Institute of Basic Medicine and Cancer (IBMC), and the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital). He received his PhD in Biomedical Engineering with the highest honor from Shanghai Jiao Tong University, China before completing postdoctoral training in cancer biology, pharmacology, and molecular therapeutics at Texas Tech University Health Sciences Center (TTUHSC). Following this he was appointed as Senior Research Associate at the university. Dr. Qin’s research mainly focuses on the discovery and development of novel, effective, and safe anticancer agents as well as demonstrating the molecular targets and mechanisms of action. He has published more than 120 research papers and reviews. He is an Associate Editor of Frontiers in Pharmacology and Frontiers in Oncology and an editorial board member of more than 10 scientific journals.

Dr. Xin Luan received his B.Sc. in Pharmaceutics from China Pharmaceutical University (2011) and was awarded his PhD degree in Pharmacology at Shanghai Jiao Tong University (2016). He subsequently worked for two years as post-doctor at the University of Michigan under the guidance of Professor Duxin Sun. In 2018, he joined Shanghai University of Traditional Chinese Medicine (SHUTCM), and is currently appointed as a professor. He is currently working on anti-tumor pharmacology and delivery systems of natural products. Dr. Luan has published more than 60 research papers and reviews.

Dr. Weidong Zhang obtained his BSc and Master degree in Natural Medicinal Chemistry from the Second Military Medical University in 1988 and 1991, respectively. He received his PhD in Natural Medicinal Chemistry from the Shanghai Institute of Pharmaceutical Industry (1998), under the supervision of Professor HuiTing Li. He is currently a professor of the Shanghai University of Traditional Chinese Medicine and Second Military Medical University. His research mainly focuses on Chinese medicine formulas, isolation, structural identification and modification, total synthesis, and structure–activity relationships of bioactive natural products. Dr. Zhang has published more than 500 peer-reviewed research papers and reviews.